SchizophreniaPhase 3TaSCSNCT02308956
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
A Phase 3 study testing Integrated mental health in primary care and Psychiatric nurse-led specialist care in people with Schizophrenia and Bipolar Disorder, run by University of Cape Town at 1 site in Ethiopia.
Trial summary
Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries. Read more about this study
- Who is it for?
- Ages 25 years and older
- Conditions the study is for
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- What is being tested?
- Integrated mental health in primary care and Psychiatric nurse-led specialist care
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 324 participants
- Where
- 1 siteEthiopia
- Study dates
- Mar 2015to 16 Nov 2017
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant in the ongoing Butajira SMD cohort study (at baseline (between 1998 and 2001), cohort participants were aged between 15 and 49 years, resident in the area for at least six months and had a DSM-IV (SCAN) diagnosis of schizophrenia or schizoaffective disorder, bipolar disorder or major depressive disorder)
- Ongoing need for continuing mental health care due to:
- being on psychotropic medication at assessment or,
- not on medication but symptomatic at the time of assessment, or
- have experienced partial or full relapse within the two years preceding the assessment
- Stable clinical condition: either in remission from SMD or with residual symptoms that have been stable over the preceding three months.
Show all 11Show fewer
- Planning to stay resident in the area for 18 months.
- Able to communicate in Amharic, the official language of Ethiopia.
- Willing to be randomised to either of the service models as described in the protocol.
- Has capacity to consent to participation or permission given by guardian and not refusing to participate
- Resident in catchment area of TaSCS health centres (excluding Butajira health centre)
Who cannot join
- Suicide attempt within the preceding three months
- Current active suicide intent
- Prescribed Thioridazine, Valproate, Lithium or second generation antipsychotic medications (Risperidone and Olanzapine), as these medications are not be available in psychiatric nurse-led units or PHC settings in Ethiopia. Within the Butajira SMD cohort, only people who have received care from psychiatrist-led units in the capital city, Addis Ababa, might be receiving these medications. At present, fewer than 10 patients are known to be taking one of these medications.
- Prescribed depot medication
- Complex or unstable medical condition interfering with management of psychiatric disorder or requiring ongoing medical treatment from Butajira hospital
- Alcohol or khat dependence or abuse within the last 12 months
Show all 15Show fewer
- Pregnant or breast-feeding
- Restrained at home
- Refusing to participate in the study
- Inclusion criteria for Phase 2 As for Phase 1, but if we are unable to recruit enough participants from the existing Butajira SMD cohort then we will expand recruitment to people with SMD attending the psychiatric out-patient clinic at Butajira hospital. A semi-structured diagnostic interview will be carried out to determine diagnostic eligibility (DSM-IV diagnosis of schizophrenia or schizoaffective disorder, bipolar disorder or major depressive disorder). For participants recruited from Butajira hospital psychiatric out-patient clinic, the minimum age will be 25 years and the participants should have had their first contact with specialist mental health services at least two years prior to recruitment into the trial to ensure comparability with the Butajira SMD cohort sample.
- Current active suicide intent
- Prescribed Thioridazine, Valproate, Lithium or second generation antipsychotic medications (Risperidone and Olanzapine).
- Pregnant or breast-feeding and prescribed depot
- Refusing to participate in the study
- Medical condition requiring ongoing medical treatment from Butajira hospital
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial
Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries. In Ethiopia, it is estimated that only around 10% of people with severe mental disorders (SMDs) ever receive evidence-based treatment for their condition, largely due to scarcity of specialist mental health services. A task-sharing model of mental health care in PHC would be more affordable and accessible to the majority of persons with SMD who do not currently receive evidence-based mental health care. Furthermore, task sharing mental health care with PHC is about to be scaled up in Ethiopia in line with the National Mental Health Strategy. However, the effectiveness of the task sharing model of mental health care for people with SMD has not been evaluated systematically in a low-income country. In this study we propose to investigate non-inferiority of a task sharing model of mental health care in PHC compared to a less accessible, but more specialist, psychiatric nurse-led model of care. The specialist model of care has been demonstrated to be acceptable and associated with improved clinical outcomes for persons with SMD engaged in the service in Ethiopia thus making this an appropriate comparison model against which to evaluate non-inferiority of the task sharing model.
Read the detailed description
Background and rationale Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries. In Ethiopia, it is estimated that only around 10% of people with severe mental disorders (SMDs) ever receive evidence-based treatment for their condition, largely due to scarcity of specialist mental health services. A task-sharing model of mental health care in PHC would be more affordable and accessible to the majority of persons with SMD who do not currently receive evidence-based mental health care. Furthermore, task sharing mental health care with PHC is about to be scaled up in Ethiopia in line with the National Mental Health Strategy. However, the effectiveness of the task sharing model of mental health care for people with SMD has not been evaluated systematically in a low-income country. In this study we propose to investigate non-inferiority of a task sharing model of mental health care in PHC compared to a less accessible, but more specialist, psychiatric nurse-led model of care. The specialist model of care has been demonstrated to be acceptable and associated with improved clinical outcomes for persons with SMD engaged in the service in Ethiopia thus making this an appropriate comparison model against which to evaluate non-inferiority of the task sharing model.
Methods Setting Meskan and Mareko districts, Gurage Zone, and Silti Zone, Southern Nations, Nationalities and People's Region, Ethiopia.
Design A parallel group, randomized, single-blinded, controlled non-inferiority trial.
Participants Adults (aged between 25 and 65 years) with severe mental disorders (DSM-IV diagnoses of schizophrenia or schizoaffective disorder, bipolar disorder or major depressive disorder) of a severity requiring continuing care who were (1) identified during a population-based survey carried out between 1998 and 2001, and are still under active follow-up, or (2) recruited from Butajira hospital psychiatric outpatient clinic.
Participants will be recruited and randomised in two phases. Phase 1 will include participants who are clinically stable, not pregnant or breastfeeding, not on depot medication and who have no co-morbid substance use or complex medical conditions. After a three month evaluation period, and if no safety or quality issues arise, the study will proceed to Phase 2. Phase 2 will include participants who have more complex needs or are less clinically stable.
New intervention Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into PHC. The intervention will be offered for 18 months.
Comparison intervention Participants in the active control arm will receive the established model of specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
General objective To determine the acceptability, affordability, effectiveness and sustainability of mental health care for persons with SMD delivered by trained and supervised non-specialist, primary health care workers compared with an existing psychiatric nurse-led service.
Specific objectives For persons suffering from SMD in Butajira, Ethiopia,
- To determine the effectiveness and cost-effectiveness of task sharing mental health care with PHC, compared to psychiatric nurse-led mental health care, on the primary outcome measure of symptom severity and on a series of secondary outcome measures.
- To examine factors influencing the implementation of the task sharing intervention and future scale up, by examining feasibility, sustainability, quality, and safety, and by qualitative exploration of the experience of task sharing from the perspectives of both PHC workers and patients.
Hypothesis Persons with SMD who receive mental health care task-shared with PHC will have a non-inferior clinical outcome, defined as a difference in the mean symptom score on the Brief Psychiatric Rating Scale, expanded version (BPRS-E), of no more than six points higher, compared to persons with SMD who receive a psychiatric nurse-led model of mental health care, after 12 months of care under the comparison service models.
Sample size A total of 324 participants (162 in each arm) will be required to detect a six point higher mean BPRS-E score in the new intervention arm compared to the active control arm, at 90% power and 95% confidence, allowing for 30% refusals and loss to follow-up (n = 124 for Phase 1 and n = 200 for Phase 2).
Randomisation Sequence generation: Computerized generation of randomization list. Blocked randomization stratified by health centre catchment area.
Allocation concealment: Labelled, sealed envelopes containing cards with intervention allocation administered by an independent clinician.
Implementation: Enrollment will occur after participants have been screened for eligibility, given informed consent (or permission given by guardian) and undergone baseline evaluation. After enrollment, an independent clinician will inform the participant of their allocation status.
Concealment Partial concealment. Outcome assessment and data analysis will be carried out by investigators who are masked to the intervention allocation of participants.
Statistical methods Intention to treat will be the primary approach to data analysis, but per protocol analyses will also be used as this is thought to more conservative in the case of non-inferiority trials. The primary outcome measure will be analysed using linear regression adjusting for baseline symptom severity measured using BPRS-E.
- Being tested
- Integrated mental health in primary care, Psychiatric nurse-led specialist care
- Keywords
- task sharing, task shifting, community mental health care, primary care, Developing country, Sub-Saharan Africa, non-inferiority trial
- Medical subject headings
- Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Integrated mental health in primary careBehavioural
A task-shared model of collaborative mental health care integrated into the primary care setting.
Psychiatric nurse-led specialist careBehavioural
A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
| Study group | Role | What they receive |
|---|---|---|
| Integrated mental health in primary care | Experimental | Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders. Receives: Behavioral: Integrated mental health in primary care |
| Psychiatric nurse-led specialist care | Active comparator | Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers. Receives: Behavioral: Psychiatric nurse-led specialist care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Brief Psychiatric Rating Scale, Expanded Version (BPRS-E)
Symptom severity scale. Non-inferiority of the experimental intervention is defined as less than six point difference in BPRS-E score between the two arms.
Measured: 12 months post-randomisation (18 months for secondary outcome)
Secondary outcomes (13)
WHO Disability Assessment Scale, version 2.0 (WHODAS 2.0)
Generic disability scale.
Measured: 12 and 18 months post-randomisation
Local functioning scale (disability scale for people with severe mental disorders developed specifically for this trial)
Contextually appropriate l.
Measured: 12 and 18 months post-randomisation
Relapse of mental disorder (Measured using the Life Chart Schedule)
Measured using the Life Chart Schedule
Measured: 12 and 18 months post-randomisation
Patient service satisfaction (Newly developed 'mental health service satisfaction scale' and qualitative interviews.)
Newly developed 'mental health service satisfaction scale' and qualitative interviews.
Measured: 12 and 18 months post-randomisation
Nutritional status (Body mass index.)
Body mass index.
Measured: 12 and 18 months post-randomisation
Service use for physical health care (Client Service Receipt Inventory)
Captured through reimbursement mechanisms and the Client Service Receipt Inventory
Measured: 12 and 18 months post-randomisation
Medication side effects (Antipsychotic Side effect Checklist)
Measured using the Antipsychotic Side effect Checklist
Measured: 12 and 18 months post-randomisation
Patient adherence and engagement (Medication Adherence Measure and tracking of appointment attendance.)
Medication Adherence Measure and tracking of appointment attendance.
Measured: 12 and 18 months post-randomisation
Stigma (Family Interview Schedule (caregivers)
Internalised stigma of mental illness (patients) and the Family Interview Schedule (caregivers)
Measured: 12 and 18 months post-randomisation
Restraint (Proportion chained, restrained of confined in the past month.)
Proportion chained, restrained of confined in the past month.
Measured: 12 and 18 months post-randomisation
Adverse event
Life Chart Schedule and tracking of serious adverse events.
Measured: 12 and 18 months post-randomisation
Quality of clinical care (WHO's mental health gap intervention guide)
Systematic evaluation of quality of documented care compared to evidence-based recommendations in WHO's mental health gap intervention guide.
Measured: 12 and 18 months post-randomisation
Acceptability and feasibility (in-depth interviews with patients, caregivers and health care providers.)
Qualitative study using in-depth interviews with patients, caregivers and health care providers.
Measured: 6 months post-randomisation onwards
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2014 (estimated)
- Study startMar 2015
- Primary completion16 May 2017
- Study completion16 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 324 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Cape Town
- Sponsor type
- University, hospital or other
- Collaborators
- Addis Ababa University, King's College London, Johns Hopkins University, Columbia University, Armauer Hansen Research Institute, Ethiopia
- Responsible party
- Principal investigator, Charlotte Hanlon, Addis Ababa University
- Investigators
- Charlotte Hanlon, BM BS, PhD, Principal investigator, Addis Ababa University and King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02308956
- Sponsor's protocol ID
- NIH-95699 (Ethiopia)
- Acronym
- TaSCS
- Status last verified
- Nov 2017
- First submitted
- 3 Dec 2014
- Last updated
- 29 Nov 2017
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D, Beyero T, Medhin G, Negash A, Kullgren G. Clinical course and outcome of schizophrenia in a predominantly treatment-naive cohort in rural Ethiopia. Schizophr Bull. 2009 May;35(3):646-54. doi: 10.1093/schbul/sbn029. Epub 2008 Apr 29.
PubMed 18448478Federal Democratic Republic of Ethiopia Ministry of Health (2012). National Mental Health Strategy, 2012/13-2015/16. Addis Ababa, Ministry of Health.
mhGAP: Mental Health Gap Action Programme: Scaling Up Care for Mental, Neurological and Substance Use Disorders. Geneva: World Health Organization; 2008. Available from http://www.ncbi.nlm.nih.gov/books/NBK310851/
PubMed 26290926Overall, J. and D. Gorham (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10: 799-812.
Hanlon C, Medhin G, Dewey ME, Prince M, Assefa E, Shibre T, Ejigu DA, Negussie H, Timothewos S, Schneider M, Thornicroft G, Wissow L, Susser E, Lund C, Fekadu A, Alem A. Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial. Lancet Psychiatry. 2022 Jan;9(1):59-71. doi: 10.1016/S2215-0366(21)00384-9.
PubMed 34921796Hanlon C, Alem A, Medhin G, Shibre T, Ejigu DA, Negussie H, Dewey M, Wissow L, Prince M, Susser E, Lund C, Fekadu A. Task sharing for the care of severe mental disorders in a low-income country (TaSCS): study protocol for a randomised, controlled, non-inferiority trial. Trials. 2016 Feb 11;17:76. doi: 10.1186/s13063-016-1191-x.
PubMed 26865254
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial
- ClinicalTrials.gov ID
- NCT02308956
- Acronym / sponsor ID
- TaSCS / NIH-95699 (Ethiopia)
- Keywords
- task sharing, task shifting, community mental health care, primary care, Developing country, Sub-Saharan Africa, non-inferiority trial
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 324 participants (actual)
- Lead sponsor
- University of Cape TownUniversity, hospital or other
- Collaborators
- Addis Ababa University, King's College London, Johns Hopkins University, Columbia University, Armauer Hansen Research Institute, Ethiopia
- Study start
- Mar 2015
- Primary completion
- 16 May 2017 (actual)
- Study completion
- 16 Nov 2017 (actual)
- First posted
- 5 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries. In Ethiopia, it is estimated that only around 10% of people with severe mental disorders (SMDs) ever receive evidence-based treatment for their condition, largely due to scarcity of specialist mental health services. A task-sharing model of mental health care in PHC would be more affordable and accessible to the majority of persons with SMD who do not currently receive evidence-based mental health care. Furthermore, task sharing mental health care with PHC is about to be scaled up in Ethiopia in line with the National Mental Health Strategy. However, the effectiveness of the task sharing model of mental health care for people with SMD has not been evaluated systematically in a low-income country. In this study we propose to investigate non-inferiority of a task sharing model of mental health care in PHC compared to a less accessible, but more specialist, psychiatric nurse-led model of care. The specialist model of care has been demonstrated to be acceptable and associated with improved clinical outcomes for persons with SMD engaged in the service in Ethiopia thus making this an appropriate comparison model against which to evaluate non-inferiority of the task sharing model.
Detailed description
Background and rationale Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries. In Ethiopia, it is estimated that only around 10% of people with severe mental disorders (SMDs) ever receive evidence-based treatment for their condition, largely due to scarcity of specialist mental health services. A task-sharing model of mental health care in PHC would be more affordable and accessible to the majority of persons with SMD who do not currently receive evidence-based mental health care. Furthermore, task sharing mental health care with PHC is about to be scaled up in Ethiopia in line with the National Mental Health Strategy. However, the effectiveness of the task sharing model of mental health care for people with SMD has not been evaluated systematically in a low-income country. In this study we propose to investigate non-inferiority of a task sharing model of mental health care in PHC compared to a less accessible, but more specialist, psychiatric nurse-led model of care. The specialist model of care has been demonstrated to be acceptable and associated with improved clinical outcomes for persons with SMD engaged in the service in Ethiopia thus making this an appropriate comparison model against which to evaluate non-inferiority of the task sharing model.
Methods Setting Meskan and Mareko districts, Gurage Zone, and Silti Zone, Southern Nations, Nationalities and People's Region, Ethiopia.
Design A parallel group, randomized, single-blinded, controlled non-inferiority trial.
Participants Adults (aged between 25 and 65 years) with severe mental disorders (DSM-IV diagnoses of schizophrenia or schizoaffective disorder, bipolar disorder or major depressive disorder) of a severity requiring continuing care who were (1) identified during a population-based survey carried out between 1998 and 2001, and are still under active follow-up, or (2) recruited from Butajira hospital psychiatric outpatient clinic.
Participants will be recruited and randomised in two phases. Phase 1 will include participants who are clinically stable, not pregnant or breastfeeding, not on depot medication and who have no co-morbid substance use or complex medical conditions. After a three month evaluation period, and if no safety or quality issues arise, the study will proceed to Phase 2. Phase 2 will include participants who have more complex needs or are less clinically stable.
New intervention Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into PHC. The intervention will be offered for 18 months.
Comparison intervention Participants in the active control arm will receive the established model of specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
General objective To determine the acceptability, affordability, effectiveness and sustainability of mental health care for persons with SMD delivered by trained and supervised non-specialist, primary health care workers compared with an existing psychiatric nurse-led service.
Specific objectives For persons suffering from SMD in Butajira, Ethiopia,
- To determine the effectiveness and cost-effectiveness of task sharing mental health care with PHC, compared to psychiatric nurse-led mental health care, on the primary outcome measure of symptom severity and on a series of secondary outcome measures.
- To examine factors influencing the implementation of the task sharing intervention and future scale up, by examining feasibility, sustainability, quality, and safety, and by qualitative exploration of the experience of task sharing from the perspectives of both PHC workers and patients.
Hypothesis Persons with SMD who receive mental health care task-shared with PHC will have a non-inferior clinical outcome, defined as a difference in the mean symptom score on the Brief Psychiatric Rating Scale, expanded version (BPRS-E), of no more than six points higher, compared to persons with SMD who receive a psychiatric nurse-led model of mental health care, after 12 months of care under the comparison service models.
Sample size A total of 324 participants (162 in each arm) will be required to detect a six point higher mean BPRS-E score in the new intervention arm compared to the active control arm, at 90% power and 95% confidence, allowing for 30% refusals and loss to follow-up (n = 124 for Phase 1 and n = 200 for Phase 2).
Randomisation Sequence generation: Computerized generation of randomization list. Blocked randomization stratified by health centre catchment area.
Allocation concealment: Labelled, sealed envelopes containing cards with intervention allocation administered by an independent clinician.
Implementation: Enrollment will occur after participants have been screened for eligibility, given informed consent (or permission given by guardian) and undergone baseline evaluation. After enrollment, an independent clinician will inform the participant of their allocation status.
Concealment Partial concealment. Outcome assessment and data analysis will be carried out by investigators who are masked to the intervention allocation of participants.
Statistical methods Intention to treat will be the primary approach to data analysis, but per protocol analyses will also be used as this is thought to more conservative in the case of non-inferiority trials. The primary outcome measure will be analysed using linear regression adjusting for baseline symptom severity measured using BPRS-E.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Integrated mental health in primary care | Experimental | Behavioral: Integrated mental health in primary careParticipants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders. |
| Psychiatric nurse-led specialist care | Active comparator | Behavioral: Psychiatric nurse-led specialist careParticipants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers. |
Who may qualify
- Ages
- 25 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Participant in the ongoing Butajira SMD cohort study (at baseline (between 1998 and 2001), cohort participants were aged between 15 and 49 years, resident in the area for at least six months and had a DSM-IV (SCAN) diagnosis of schizophrenia or schizoaffective disorder, bipolar disorder or major depressive disorder)
- Ongoing need for continuing mental health care due to:
- Stable clinical condition: either in remission from SMD or with residual symptoms that have been stable over the preceding three months.
- Planning to stay resident in the area for 18 months.
- Able to communicate in Amharic, the official language of Ethiopia.
Key exclusion criteria (15 listed)
- Suicide attempt within the preceding three months
- Current active suicide intent
- Prescribed Thioridazine, Valproate, Lithium or second generation antipsychotic medications (Risperidone and Olanzapine), as these medications are not be available in psychiatric nurse-led units or PHC settings in Ethiopia. Within the Butajira SMD cohort, only people who have received care from psychiatrist-led units in the capital city, Addis Ababa, might be receiving these medications. At present, fewer than 10 patients are known to be taking one of these medications.
- Prescribed depot medication
- Complex or unstable medical condition interfering with management of psychiatric disorder or requiring ongoing medical treatment from Butajira hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Integrated mental health in primary careA task-shared model of collaborative mental health care integrated into the primary care setting. | Behavioural | Integrated mental health in primary care |
| Psychiatric nurse-led specialist careA centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers | Behavioural | Psychiatric nurse-led specialist care |
Primary outcome
Brief Psychiatric Rating Scale, Expanded Version (BPRS-E)
Time frame: 12 months post-randomisation (18 months for secondary outcome)
Symptom severity scale. Non-inferiority of the experimental intervention is defined as less than six point difference in BPRS-E score between the two arms.
13 secondary outcomes
WHO Disability Assessment Scale, version 2.0 (WHODAS 2.0)
Time frame: 12 and 18 months post-randomisation
Local functioning scale (disability scale for people with severe mental disorders developed specifically for this trial)
Time frame: 12 and 18 months post-randomisation
Relapse of mental disorder (Measured using the Life Chart Schedule)
Time frame: 12 and 18 months post-randomisation
Patient service satisfaction (Newly developed 'mental health service satisfaction scale' and qualitative interviews.)
Time frame: 12 and 18 months post-randomisation
Nutritional status (Body mass index.)
Time frame: 12 and 18 months post-randomisation
Service use for physical health care (Client Service Receipt Inventory)
Time frame: 12 and 18 months post-randomisation
Medication side effects (Antipsychotic Side effect Checklist)
Time frame: 12 and 18 months post-randomisation
Patient adherence and engagement (Medication Adherence Measure and tracking of appointment attendance.)
Time frame: 12 and 18 months post-randomisation
Stigma (Family Interview Schedule (caregivers)
Time frame: 12 and 18 months post-randomisation
Restraint (Proportion chained, restrained of confined in the past month.)
Time frame: 12 and 18 months post-randomisation
Adverse event
Time frame: 12 and 18 months post-randomisation
Quality of clinical care (WHO's mental health gap intervention guide)
Time frame: 12 and 18 months post-randomisation
Acceptability and feasibility (in-depth interviews with patients, caregivers and health care providers.)
Time frame: 6 months post-randomisation onwards
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2017.
- Background: PubMed 18448478Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D, Beyero T, Medhin G, Negash A, Kullgren G. Clinical course and outcome of schizophrenia in a predominantly treatment-naive cohort in rural Ethiopia. Schizophr Bull. 2009 May;35(3):646-54. doi: 10.1093/schbul/sbn029. Epub 2008 Apr 29.
- BackgroundFederal Democratic Republic of Ethiopia Ministry of Health (2012). National Mental Health Strategy, 2012/13-2015/16. Addis Ababa, Ministry of Health.
- Background: PubMed 26290926mhGAP: Mental Health Gap Action Programme: Scaling Up Care for Mental, Neurological and Substance Use Disorders. Geneva: World Health Organization; 2008. Available from http://www.ncbi.nlm.nih.gov/books/NBK310851/
- BackgroundOverall, J. and D. Gorham (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10: 799-812.
- Derived from this study: PubMed 34921796Hanlon C, Medhin G, Dewey ME, Prince M, Assefa E, Shibre T, Ejigu DA, Negussie H, Timothewos S, Schneider M, Thornicroft G, Wissow L, Susser E, Lund C, Fekadu A, Alem A. Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial. Lancet Psychiatry. 2022 Jan;9(1):59-71. doi: 10.1016/S2215-0366(21)00384-9.
- Derived from this study: PubMed 26865254Hanlon C, Alem A, Medhin G, Shibre T, Ejigu DA, Negussie H, Dewey M, Wissow L, Prince M, Susser E, Lund C, Fekadu A. Task sharing for the care of severe mental disorders in a low-income country (TaSCS): study protocol for a randomised, controlled, non-inferiority trial. Trials. 2016 Feb 11;17:76. doi: 10.1186/s13063-016-1191-x.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charlotte Hanlon, BM BS, PhD principal investigator
Addis Ababa University and King's College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Integrated mental health in primary care and Psychiatric nurse-led specialist care in people with Schizophrenia and Bipolar Disorder, run by University of Cape Town at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Brief Psychiatric Rating Scale, Expanded Version (BPRS-E) (time frame: 12 months post-randomisation (18 months for secondary outcome)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02308956, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2017.